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ABSTRACT
We systematically studied the association between
somatic copy number aberration (SCNA), DNA
methylation and gene expression using -omic data
from The Cancer Genome Atlas (TCGA) on six can-
cer types: breast cancer, colon cancer, glioblastoma,
leukemia, lower-grade glioma and prostate cancer.
A major challenge for such integrated study is that
the association between DNA methylation and gene
expression is severely confounded by tumor purity
and cell type composition, which are often unob-
served and difficult to estimate. To overcome this
challenge, we developed a method to remove con-
founding effects by calculating the principal compo-
nents that span the space of the latent factors. An-
other intriguing findings of our study is that there
could be both positive and negative associations be-
tween SCNA and DNA methylation, while the CpGs
with negative/positive associations with SCNA are
often located around CpG islands/ocean, respec-
tively. A joint study of SCNA, DNA methylation, and
gene expression suggest that SCNA often affect DNA
methylation and gene expression independently.
INTRODUCTION
Cancer arises from the accumulation of somatic DNA aber-
rations and epigenetic modifications that alter transcrip-
tion, protein products, and cell behavior. Thus, studies of
molecular features such as gene expression or DNA methy-
lation may inform the underlying mechanism of carcinogen-
esis and progression. The Cancer Genome Atlas (TCGA)
project has collected multiple types of -omic data from
>10 000 tumor samples (1), and this dataset allows sys-
tematic study of the genetic or epigenetic basis of cancer.
Many previous TCGA studies focus on each types of -
omic data in order to identify genetic loci/pathways with
more somatic alterations/perturbations than expected by
chance. Other studies have examined multiple types of -
omic data to identify tumor subtypes or driver pathways.
Several methods and results have been published for the in-
tegrated analysis of multiple types of -omic data (2,3). For
example, Shen et al. (4) developed an integrative clustering
approach (iCluster) and used it to identify molecular sub-
types for breast, lung and colon cancers. Wang et al. (5) in-
tegrated different types of omic data using a hierarchical
Bayesian model called ‘integrative Bayesian analysis of ge-
nomics data’ (iBAG). Zhu et al. (6) have used multiple types
of omic data to predict survival time.
TCGA data also provide rare resources to systemati-
cally study the interplay between different types of -omic
features, such as the association between gene expres-
sion trait and genetic variation, known as gene expres-
sion quantitative trait locus (eQTL) analysis (7). Anal-
ogous to eQTL, the genetic basis of DNA methylation
has also been studied (8). In this paper, using the -omic
data from TCGA, we systematically studied the associ-
ation between somatic copy number aberration (SCNA),
DNA methylation, and gene expression for six types of can-
cers: breast cancer (BRCA), colon cancer (COAD), acute
myeloid leukemia (LAML), glioblastoma (GBM), lower-
grade glioma (LGG) and prostate cancer (PRAD).
DNA methylation is one of the most widely studied
epigenetic marks in cancer genome. Genome-wide hypo-
methylation and hyper-methylation at some gene promot-
ers have been observed in multiple types of cancer (9). Epi-
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genetic marks such as chromatin organization or DNA
methylation are often associated with the regulation of
gene expression. Thus, studies on the association between
DNA methylation and gene expression are critical to un-
derstanding the functional role of DNA methylation in can-
cer (10,11). It has been reported that DNA methylation at
promoter regions is often negatively associated with gene
expression while DNA methylation in gene bodies is often
positively associated with gene expression (12). However,
the functional role of DNA methylation (i.e. whether DNA
methylation is a passive mark of transcription activity or an
active regulator that modifies gene expression) is still being
debated (13).
In this paper, we systematically studied the functional
role of DNA methylation by jointly analyzing -omic data
of SCNA, gene expression and DNA methylation. Toward
this end, we developed a new method to accurately estimate
the association between gene expression and DNA methy-
lation by removing the confounding effect caused by tumor
purity and cell type composition.
MATERIALS AND METHODS
For each type of cancer, we selected samples with associ-
ated clinical data plus all three types of -omic data, and we
filtered out samples of rare tissue sites or plates (Supple-
mentary Figure S1). For the breast cancer study, we also
restricted our analysis to those samples with tumor pu-
rity, ploidy and subtype information. To avoid possible con-
founding due to race, we chose to study tumor samples
from Caucasian samples, as inferred from genotype Prin-
cipal component analysis (PCA) of both HapMap samples
and all TCGA samples within a cancer type (Supplemen-
tary Figure S2). Then, we performed PCA again on the se-
lected Caucasian samples and used the resulting top PCs as
part of the demographical covariates.
We included the following 3 groups of covariates when
we assessed associations: (i) batch effects, including tissue
sites and plates (Supplementary Figure S3); (ii) demograph-
ical covariates such as age, gender, and genotype PCs to ac-
count for population stratification and (iii) cancer subtypes
when such information was available. Specifically, for breast
cancer, we employed the subtype inferred from gene expres-
sion data: Basal, Her2, LumA, LumB and Normal (14). For
colon cancer, we partitioned the samples into two groups:
hyper-mutated tumors and non-hyper-mutated tumors (15).
The hyper-mutated tumors are defined as those with >1000
point mutation calls from exome-seq data. Subtype infor-
mation for glioblastoma was taken from a recent publica-
tion (16) that classifies patients into 4 expression subtypes:
classical, mesenchymal, neural and proneural, and addi-
tionally, a subgroup of G-CIMP based on methylation data.
The subtype of lower-grade glioma was decided by IDH1/2
mutation and chromosome 1p/19q deletion (17). The sub-
types of acute myeloid leukemia were defined by cytoge-
netic risk group (18). There were no well-defined subtypes
for prostate cancer, and thus, we did not include subtypes
in our analysis for prostate cancer.
The SCNA data were level 3 data from the TCGA data
portal after segmentation of probe-level data. More specif-
ically, the probe-level SCNA data of each individual were
obtained from Affymetrix 6.0 array using log ratio of the
intensity of the tumor sample versus the intensity of the
paired-normal sample. Such measurement of SCNA is of-
ten referred to as LRR (log R ratio), which quantifies un-
derlying copy number changes, i.e. higher values indicate
copy number gain and lower values indicate copy number
loss. Such LRR values were segmented by circular binary
segmentation (CBS) and saved as level 3 data in TCGA
data portal. We used gene-level SCNA data by taking the
segmental mean of the corresponding gene (Supplementary
Figures S4 and S5).
The DNA methylation data were analyzed for each CpG
separately (Supplementary Figure S6). The gene expres-
sion data were summarized by read count per gene and per
sample, normalized by sample-specific read-depth (Supple-
mentary Figure S7). The gene expression and DNA methy-
lation data were further transformed using normal quan-
tile transformation for each gene and each CpG separately.
This transformation is commonly used in large-scale eQTL
studies to obtain more robust results when there is non-
linear relations or outliers (19). Overall the methylation-
expression association strength estimated before and af-
ter normal quantile transformation are similar (Supple-
mentary Figure S10), suggesting that linear relation is rea-
sonable for most methylation-expression associations. We
have illustrated such linear relations for a few CpG-gene
pairs (Supplementary Figure S16). Previous studies have re-
ported highly non-linear relation between methylation and
gene expression when examining all the genes within one in-
dividual (20,21). In contrast, our focus is the association of
one gene and one CpG across individuals. The across in-
dividual associations may not have the same property as
across gene associations (22). We used MatrixEQTL (23) for
all computation to assess pairwise associations of SCNA,
DNA methylation, and gene expression.
In order to assess methylation-expression (ME) associa-
tions while accounting for the effects of tumor purity and
cell type composition, we proposed to identify the subspace
spanned by tumor purity and cell type composition using
top PCs from PCA of significantly associated distant ME
pairs. Specifically, we first performed the ME association
analysis for each ME pair, while accounting for the effects
of all other covariates such as batch effect, demographical
variables, cancer subtypes, as well as the SCNA of the cor-
responding gene. Then, we selected those significantly asso-
ciated ME pairs that are not located on the same chromo-
somes. Suppose that K such ME pairs are selected. Denote
the methylation and expression data of each pair as Mk and
Ek, respectively. Note that both Mk and Ek are vectors of
length n, where n is the sample size. We regressed Mk and
Ek against all other covariates and obtained residuals. We
then standardized the residuals to have mean 0 and stan-
dard deviation 1 and denoted the resulting data by M̃k and
Ẽk. The association between Mk and Ek could be positive
or negative. k is the regression coefficient of regressing Ek
versus Mk, and thus sign(k) > 0 means gene expression
increases as methylation increases. We took the average of
M̃k and Ẽksign(βk), denoted by ηk = [M̃k + Ẽksign(βk)]/2,
which is a vector of length n. Let  = (1, 2, ..., K)T, which
is a matrix of size K × n. We performed PCA on  and then
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used the resulting PCs (referred to as ME PCs) as covariates
in ME association testing. It is reasonable to take average
of M̃k and Ẽksign(βk) because we want to identify the sig-
nals shared between M̃k and Ẽksign(βk), and they are on the
same scale after standardization.
The above procedure implicitly assumes the vast major-
ity of the distant ME associations are false positives due to
tumor purity or cell type composition. If this conjecture is
true, then a few top PCs can explain most variation in the
data. We have confirmed this in our data analysis. For ex-
ample, for breast cancer, the top 7 PCs explains >92% of
the variation of >136 000 distant ME pairs (Supplemen-
tary Figure S13). This situation fits to the ‘spiked eigenvalue
model’ for high-dimensional data where a few population
eigenvalues are substantially larger than the rest. We refer
the readers to (24,25) for more details of the statistical prop-
erty of eigen-values and eigen-vectors in such settings.
Then a related question is how to decide the number of
ME PCs to use. These ME PCs are calculated based on dis-
tant ME associations and some of those distant associations
may be true biological signals. Therefor if we include too
many ME PCs in the analysis, there is risk to remove such
true distant ME associations. We believe that the choice on
the number of ME PCs does not impose serious limitations
on our approach because those true distant ME association
signals are usually weak and sparse, and thus may not lead
to ME PCs with relatively large eigen-values. From our ex-
perience, there are a few helpful guidelines. First, one may
choose the cutoff of the number of top ME PCs where there
is apparent drop on the size of eigen-values. Second, one can
choose the smallest number of top ME PCs such that after
adjusting for those ME PCs, most methylation-expression
associations are local. Additionally, we may exclude those
ME PCs that are associated with the methylation of CpGs
within a short genomic region, because such ME PCs may
be due to eQTM (expression quantitative trait methylation)
hotspots where the methylation of a short genomic region
is associated with the expression of many genes.
RESULTS
We will mainly report the results from the breast cancer
data. The results from other types of cancer are similar and
are reported in the Supplementary Materials.
SCNA versus gene expression or DNA methylation
The vast majority of the SCNA-expression and SCNA-
methylation associations are local, meaning that the SCNA
of a gene affects gene expression or DNA methylation in
nearby genomic regions (Figure 1A and B, Supplementary
Figures S21–S25). As expected, SCNAs are positively asso-
ciated with gene expression. We are not aware of any previ-
ous systematic studies on the association between SCNA
and DNA methylation. We found that such associations
can be positive or negative. When they have negative asso-
ciations (i.e. DNA methylation decreases with copy num-
ber gain and DNA methylation increases with copy number
loss), the corresponding CpGs are often located at CpG is-
lands (Figure 1C and D, Supplementary Figures S26–S30).
In contrast, positive associations between SCNA and DNA
methylation are often observed on those CpG’s located at
CpG ocean.
We accounted for both technical and demographic/clin
ical covariates in our analyses. The technical batch effects
(e.g. tissue collection sites, plates for sample handling) of-
ten have a very strong influence on gene expression or DNA
methylation (Supplementary Figure S3). We also included
cancer subtypes in our analysis (see Materials and Meth-
ods section for the definition of cancer subtypes). Failure
to account for cancer subtypes may lead to misleading re-
sults. For example, in breast cancer studies, without condi-
tioning on the subtypes of breast cancer, one may identify
associations due to subtype-specific SCNA, DNA methy-
lation and gene expression (Supplementary Figures S8 and
S9), including some confusing results, such as negative asso-
ciations between SCNA and gene expression. Another po-
tential confounding factor is tumor purity. Adding tumor
purity as an additional covariate does not remove much of
the SCNA-methylation or SCNA-expression associations.
For example, for breast cancer and at p-value cutoff 1e–30,
we identified around 328,000 SCNA-methylation associa-
tions without purity as a covariate. After including purity
as a covariate, we can recover around 88% or 98% of these
328 000 SCNA-methylation associations at P-value cutoff
1e–30 and 1e–28, respectively.
After accounting for all the known batch effects and tu-
mor subtypes, we still observe a hotspot of SCNA vs. DNA
methylation associations in breast cancer data, where DNA
methylation of hundreds of CpGs from multiple chromo-
somes are associated with SCNA of multiple genes on chr16
(Figure 1A). This is likely due to copy number changes
of CTCF. CTCF is a well-known transcription factor that
plays important roles in epigenetic regulation. CTCF is
among those genes in chr16 whose copy number changes
are associated with many CpGs, and the gene expression of
CTCF is strongly associated with its SCNA (P-value 4.6 ×
10−50). At P-value threshold 10−20, there are 134 CpGs that
are not located in chr16 and their methylation levels are as-
sociated with at least one SCNA on chr16. Among them,
120 (97%) are located in CTCF binding sites, while we ex-
pect 5% overlap by chance. CTCF binding sites information
were obtained from CTCFBSDB 2.0 (26), see Supplemen-
tary Materials Section B.1.7 for more details. The methyla-
tion levels of these 134 CpGs are all negatively associated
with CTCF copy number, which implies that when CTCF
amplifies, the CTCF protein is more likely to bind those
binding sites, and lead to reduction of methylation in these
regions.
Gene expression versus DNA methylation
We assessed methylation-expression (ME) associations af-
ter accounting for technical and demographic/clinical co-
variates, as well as SCNA. An initial assessment identified
a huge number of significant ME associations, and most
of them were distant associations (Figure 2A). A majority,
but not all of the distant ME associations can be removed
by conditioning on SCNA-based estimates of tumor purity
(Supplementary Figure S10) (27,28). This suggests that tu-
mor purity is a confounding factor. This observation is con-
sistent with recent findings that tumor purity affects both
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Figure 1. Associations between SCNA and gene expression or DNA methylation. (A) Associations between SCNA and DNA methylation, after accounting
for the effects of batches (sites and plates), age, three genotype PCs and breast cancer subtypes. Each point in this plot indicates the association between
the SCNA of one gene (x-axis) and the DNA methylation of one probe (y-axis). The color of each point indicates the range of the corresponding –log10(P-
value), as shown in the legend at the top of the panel. The associations with P-values larger than 10–20 are not shown. (B) Associations between SCNA and
gene expression, after accounting for the effects of batches (sites and plates), age, three genotype PCs and breast cancer subtypes. (C) The distribution of the
regression coefficients of methylation Quantitate trait Copy Number (mQCN), i.e. the regression coefficients of SCNA within the model: DNA methylation
= SCNA + other covariates. (D) ‘mQCN+’ and ‘mQCN–’ indicate the DNA methylation probes that have only positive or negative associations, respectively,
with SCNA. This plot shows the proportion of mQCN+/mQCN– probes located at different regions with respect to CpG islands. CpGs were annotated
based on annotation file provided by Illumina: CpG shore are defined as 2,000 bp either side of an island with north/south shore means 5′ or 3′ relative to
the associated gene. North and south shelves are 2000 bp flanking the CpG shores. The other CpGs are referred to as ‘none’, or sometime ‘CpG ocean’ or
‘open sea’.
gene expression and DNA methylation in tumor samples
(29,30).
We developed a new computational approach that allows
us to remove ME associations due to latent confounding
factors. Specifically, we performed a joint PCA of methy-
lation and expression data for significantly associated ME
pairs (see Materials and Methods section for details) and
added the resulting PCs (referred to as ME PCs) as co-
variates when assessing ME associations. This approach re-
moved most distant ME associations even at more liberal
p-value cutoffs (Figure 2(B), Supplementary Table S4, Sup-
plementary Figures S11 and S12).
We conjecture that ME PCs capture cell type composi-
tion information within tumor tissue. The most dramatic
cell type difference is between tumor and non-tumor cells,
and indeed some of these ME PCs have strong associa-
tions with tumor purity, which was estimated by SCNA
data (Supplementary Figures S13 and S14). However, there
are also multiple types of non-tumor cells that may con-
tribute to ME associations. This explains why we need mul-
tiple PCs to remove suspicious ME associations. To vali-
date this conjecture, we examined the associations between
the top seven ME PCs and cell type-specific gene expres-
sion, which were calculated as the median expression of
cell-type-specific genes. We identified such cell-type-specific
genes from the list of 812 immune metagenes (each immune
metagene is associated with one of 31 cell types) reported
by Angelova et al. (31), and they identified such immune
metagenes by differential expression analysis of purified im-
mune cells. Each PC is associated with a variety of cell types
(Figure 3, Supplementary Figures S42–S46). Together these
seven ME PCs explain a substantial amount of variation in
cell type-specific genes. For example, for breast cancer, they
explain more than 60% of variation for 12 of 31 cell types,
and >40% of variation in 21 of 31 cell types (Supplemen-
tary Figures S47–S52). It is important to note that these
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Figure 2. Associations between DNA methylation and gene expression. (A) Associations between DNA methylation and gene expression. Each point
in this plot indicates the association between the DNA methylation of one probe (x-axis) and the expression of one gene (y-axis), after accounting for
the effects of batches (sites and plates), age, three genotype PCs, SCNA of the corresponding gene and breast cancer subtypes. The color of each point
indicates the range of the corresponding –log10(P-value), as shown in the legend at the top of the panel. (B) Association between DNA methylation and
gene expression, after including all covariates used in (A) plus seven ME PCs. (C) The proportion of ‘hot’ (‘cold’) CpGs that are located at specific regions
with respect to CpG Island. (D) The genomic location of gene expression quantitative trait methylation probes (eQTM) with respect to the location of its
associated genes. [–1,0] is the region 1 kb upstream of transcription starting site (TSS), and [0,1] corresponds to gene body. All eQTMs are divided into
two classes: those that are positively or negatively associated with gene expression, denoted by eQTM+ and eQTM–, respectively.
ME PCs jointly span a space of underlying cell type com-
position, and a specific PC may not correspond to a distinct
subset of cell types.
Having demonstrated that ME PCs capture cell type
composition information, including tumor purity, we con-
clude that by including ME PCs in our analysis, we are able
to account for such confounding effects without actually es-
timating these quantities. Without accounting for such con-
founding factors, most ME associations are false positives
in the sense that they are due to differential expression or
methylation across cell types and do not imply any func-
tional associations. Even if we only focus on those gene and
CpG pairs within 1 Mb, >90% of significant ME associa-
tions are false positives (Supplementary Figure S15).
Next, we sought to characterize those genes and CpGs
that have major contributions to the ME PCs. We can iden-
tify such genes by those ‘hot’ genes that are associated
with the methylation of a large number of CpGs. These
hot genes are expressed in different types of immune cells,
and their expression are negatively associated with tumor
purity (Supplementary Tables S5, S10–S14, Supplementary
Figure S17), suggesting that these genes have relatively low
expression in tumor and thus can be used to quantify the
amount of infiltrating immune cells. The results remain sim-
ilar if we identify hot genes based on effect size (regres-
sion coefficients) rather than P-value (Supplementary Fig-
ure S18, Supplementary Table S6). The hot CpGs are not
strongly associated with any location annotations that we
have tested, though it does have higher likelihood of being
located at CpG shores or CpG ocean (i.e. regions farther
away from CpG islands) (Figure 2C, Supplementary Fig-
ures S36–S40), which is consistent with previous findings
about cancer-specific methylation in CpG shores (16).
By accounting for those ME PCs, we have a more ac-
curate picture of the association between gene expression
and DNA methylation. Across different cancer types, we
found that gene expression is often negatively associated
with DNA methylation around Transcription Starting Sites
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Figure 3. Relations between cell type prevalence and ME PCs. The median expression of the genes annotated to each cell type was used as a surrogate for
cell type prevalence, and it was regressed against top seven ME PCs. This Figure illustrates the proportion of variance explained by each of the top seven
PCs. Values >0.5 are truncated for visualization contrast.
(TSSs), but positively associated with DNA methylation in
gene bodies (Figure 2D, Supplementary Figures S33–S37),
which is consistent with previous findings (13).
SCNA, DNA methylation, and gene expression
We further study the association of any two types of -
omic features given the third one. Since we have accounted
for SCNA in ME association studies, here we focus on
the conditional associations of SCNA and DNA methyla-
tion given gene expression (CM given E) and CE given M.
Among those cases with significant CE associations, given
M, CE associations have little changes (Supplementary Fig-
ures S53–S58), suggesting DNA methylation does not have
strong mediation role on the relations between SCNA and
gene expression.
Next we focus on those cases with significant CM asso-
ciations to study the relations of these three variables. We
perform a gene-centric analysis. For each gene, we consider
its SCNA, gene expression, and local CpGs (within 200 kp
of this gene) of which the DNA methylation is significantly
associated with the SCNA of this gene, and we ignore those
genes without any significant local CM associations (Figure
4A).
For each triplet of C, M and E, we compare three possi-
ble models, causal, reactive, and conditional independence
(Figure 4B) using likelihood ratio test for non-nested mod-
els (32). The difference of these models can be quanti-
fied by likelihood function because they entail different
conditional dependence assumption. For example, causal
model implies gene expression is independent of SCNA
given DNA methylation, i.e., the likelihood can be written
as L(C)L(M|C)L(E|M). In contrast, the likelihood for reac-
tive and conditional independence models can be written as
L(C)L(E|C)L(M|E) and L(C)L(E|C)L(M|C). Standard like-
lihood model can compare two nested models. However, in
this case, the three models are not nested with each other.
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Figure 4. Study the associations of SCNA (C), DNA methylation (M), and gene expression (E). (A) A gene-centric organization of the three types of data.
Here, we focus on those cases with significant CM associations and the CpG is with 200 kb of the gene. (B) We compare the likelihood of three models and
for each cancer type, and identify the number of CM pairs where one of the three models has significantly higher likelihood, or that the likelihoods of the
top two models are not significantly different.
Therefore we employ a likelihood ratio test for non-nested
model. Under the null hypothesis, the two non-nested mod-
els have equal distance to the underlying unknown true
model. We conclude one model fit the data better than the
other two models if the likelihood ratio test p-value for the
best versus the second best model is smaller than 0.01. We
found that the independence model fit the data better in
most cases, and this conclusion remains the same regard-
less the choice of p-value cutoff (Figure 4(B)). To further
illuminate this conclusion, we also perform three sets of
unconditional/conditional regressions for CE, CM and ME
associations. For example, for each CE pair, we asses its as-
sociation strength before and after adding DNA methyla-
tion into the regression model, while the other covariates,
such as batch effects, demographical variables (age, gender,
genotype PC), tumor subtypes, and ME PCs are always in-
cluded in the model. Similar, we compare the CM versus
CM | E associations, and ME versus ME | C associations
(Supplementary Figures S53-S58).
When we cannot distinguish top two models, i.e. the like-
lihood ratio test conclude that these two models have similar
distances to the underlying true model (Figure 4B), the un-
derlying model is likely a complete model where any two of
the three omic features are connected. In other words, this
is the situation where both DNA methylation and SCNA
make their own contributions to explain the variation in
gene expression. For example, PVT1 is a known oncogene
and is amplified in a subset of tumor samples. Copy num-
ber amplification of PVT1 is associated with higher gene ex-
pression. Given such copy number changes, we still observe
association between DNA methylation in the promoter of
PVT1 and its gene expression (Figure 5).
DISCUSSION
We have made two major contributions in this paper. One is
to report that the underlying cell type composition (e.g. tu-
mor cells versus different types of normal cells including
infiltrating immune cells) is a crucial confounding factor
when studying the associations between DNA methylation
and gene expression of tumor samples. We have developed a
computational method to remove such confounding factors
while bypassing the challenging task of inferring cell type
composition. Our method is different from surrogate vari-
able analysis (33) or supervised normalization of microar-
rays (34). They study the association between one type of
omic data (e.g. gene expression) and some covariates of in-
terest, and identify latent confounding factors by PCA of
the omic data while carefully handling the effects of known
covariates. Our work is different because we exploit the cor-
relation of two types of omic data to identify the underly-
ing latent factors. Our second major contribution is to re-
port that DNA methylation may be either positively or neg-
atively associated with somatic copy number aberrations.
Following our association study, immediate ques-
tions are the mechanisms or causal relations for those
ME (methylation-expression) or CM (copy number-
methylation) associations. Ultimately, these questions
need to be answered by experiments with carefully de-
signed interventions on the molecular system. However,
our computational analysis can provide some insights.
Previous studies have shown that hyper-methylation on
gene promoters often maintain, rather than initialize tran-
scriptional repression (13). For example, Lock et al. (35)
showed that DNA methylation occurs after inactivation of
gene expression, and Verma et al. (36) demonstrated that
promoter hypermethylation does not lead to decrease of
gene expression. Our results on the joint analysis of SCNA
(C), DNA methylation (M), and gene expression (E) are
consistent with the ‘maintainer’ role of DNA methylation.
If DNA methylation actively modifies gene expression,
given that we start with triplets with C-M associations, the
model of C, M, and E should be a causal model of C →
M → E or a full model with connections C–M, and M–E
and C–E. However, our results show that in most cases, the
most likely model is the conditional independence model in
which the variation of DNA methylation is not associated
with changes in gene expression. If methylation only plays
a ‘maintainer’ role, it remains a question what is the factor
that causes gene expression changes, and a potential route
to answer this question is to explore other epigenetic marks
such as chromatin modification or transcription factor
binding (37).
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Figure 5. An example where gene expression are associated with both SCNA and DNA methylation. (A) Scatter plots of SCNA of PVT1, the methylation
of a CpG at its promoter, and its expression. The values of SCNA and methylation are partitioned into three categories based on 25th and 75th percentiles.
(B) Distribution of gene expression with respect to SCNA and DNA methylation categories. Gene expression increases as SCNA increases and methylation
decreases.
It is an intriguing question why SCNA is associated with
DNA methylation changes. If the probability that a CpG is
methylated is cis-regulated, e.g. it is controlled by surround-
ing DNA sequence of the same allele, then DNA methy-
lation should remain the same regardless of copy number
changes. Therefore the fact that we observe strong SCNA-
methylation associations suggests that DNA methylation
level is regulated in trans upon SCNA events. The genome-
wide changes of methylation pattern upon SCNA events is
unlikely due to somatic mutations of particular proteins or
pathways, e.g. the association between DNA methylation
and copy number changes of CTCF observed in breast can-
cer patients. Instead, it is more likely to be initiated and
maintained by a generic machinery.
To understand the underlying mechanism of CM associ-
ations, we summarize the locations of the genes with signifi-
cant local CM associations (within 2 kb) as well as the mag-
nitude of methylation changes, and note three observations.
First, there is significant overlap of CM associations across
cancer types. For example, 7056 and 829 genes are involved
in local CM associations in BRCA and COAD patients at
P-value cutoffs 10−20 and 10−10, respectively. Different p-
value cutoffs are used to account for sample size difference.
About 88.7% of the 829 genes identified from COAD are
also identified in BRCA (P-value 9.7 × 10−243). Part of such
overlap can be explained by the similarity of SCNA events
across cancer types (Supplementary Figures S59–S69). An-
other observation is that genes with positive and negative
CM associations are often located next to each other, or
one gene’s expression may be positively and negatively as-
sociated with the methylation of different CpGs (Supple-
mentary Figures S65–S69). Third, the magnitude of DNA
methylation changes with respect to copy number changes
is relatively small. For example, as shown in Supplemen-
tary Figure S70, the average DNA methylation of one CpG
changes from 0.06 to 0.02 as SCNA measurement varies
from 0 to 2.0.
Based on these three observations, it is attempting to con-
jecture that the CM associations may be due to redistribu-
tion of the methylase complex in a relatively short region
of the genome, and this redistribution is not a cancer type-
specific process. For example, when there is copy number
amplification, we observe that DNA methylation decreases
around CpG islands and increases in CpG ocean. This may
be due to redistribution of DNA methylation from CpG is-
lands to nearby CpG poor regions. When there is copy num-
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ber deletion, we observe that DNA methylation increases
around CpG islands and decreases in CpG ocean, and this
may be due to redistribution of DNA methylation from
CpG ocean to nearby CpG islands. It has been reported that
oxidative damage can induce such redistribution of DNA
methylation (38). Low level increase of methylation at CpG
islands has been associated with aging and cancer, and it
may be due to redistribution of the methylase complex (39).
The magnitude of aging-associated methylation changes is
similar to what we have observed in CM associations in tu-
mor samples (40).
Such conjecture of ‘redistribution of DNA methylation’
upon copy number changes can be validated using lon-
gitudinal copy number and DNA methylation measure-
ments along the timeline of tumor initiation and progres-
sion. Without such luxury resource, we use adjacent nor-
mal tissue as an proxy of pre-tumor sample. We focus on
colon cancer due to the availability of adjacent normal sam-
ples in TCGA data and the fact that tumor cells and adja-
cent normal cells in colon cancer are likely derived from the
same set of stem cells (41). We downloaded and processed
SCNA data for 90 adjacent normal samples and we found
that there are no copy number aberrations in these adja-
cent normal samples (Supplementary Section B.4). Adja-
cent DNA methylation data were available for 38 samples.
The DNA methylation of the CpGs involved in CM associ-
ations is more similar between tumor and adjacent normal
samples than the other CpGs (Supplementary Figure S72).
This result indicates that those CpGs involved in CM asso-
ciations are not those that are differentially methylated be-
tween tumor and normal samples. Focusing on those CpGs
involved in CM associations, we found that DNA methy-
lation is more similar between tumor and normal samples
if we only considered the tumor samples with copy number
close to two (Supplementary Figure S72). Therefore, this re-
inforces the conjecture that DNA methylation is perturbed
upon copy number changes.
In addition to SCNA, it is also interesting to study the as-
sociations between gene expression/DNA methylation and
somatic point mutations such as single nucleotide variants
(SNVs) or indels. Systematic study of somatic point muta-
tion associations, which is beyond the scope of this paper,
faces the challenges of imperfect somatic mutation calling
accuracy as well as low recurrence rates of somatic muta-
tions. Here we show an interesting example. Somatic muta-
tions in IDH1/IDH2 are strongly associated with the DNA
methylation of many CpGs in lower grade glioma (LGG)
(42). In our analysis of TCGA LGG samples, we consid-
ered IDH1/IDH2 mutation as part of the tumor subtype,
and thus it does not affect our results. However, if we study
the associations between IDH mutation, DNA methylation,
and gene expression, we observed that DNA methylation
often mediates the association between IDH mutation and
gene expression. In contrast, the association between IDH
mutation and DNA methylation remains similar after con-
ditioning on gene expression (Supplementary Figure S76).
Our method to estimate the associations between gene
expression and DNA methylation allows us to bypass the
challenging task of estimating tumor purity and cell type
composition. However, these are still very important prob-
lems that warrant further studies. Currently, tumor purity
is often inferred by SCNA data (27), and cell type composi-
tion may be decomposed using gene expression data, while
ignoring tumor purity (43). Our results suggest that jointly
studying multiple types of -omic data to infer both tumor
purity and cell type composition is a promising approach.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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